title: [Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer].
abstract: Recently chemoradiotherapy for esophageal cancer has been drawing public attention to the issue of quality of life maintenance for patients. Although the standard method of chemoradiotherapy is CDDP/5FU, it has been claimed that CDGP (a derivative of CDDP) alone is more effective than CDDP for the treatment of esophageal cancer due to its low nephro- and digestive toxicity. We used a small amount of CDGP/5-FU in combination with radiation instead of CDDP, for the treatment of esophageal cancer and performed clinical examination of patients. The partial response rate was 80% and the complete response rate was 50%. Major side-effects were leukopenia, neutropenia, thrombocytopenia and anemia. Further study of dosage and schedule is necessary, however, CDGP/5-FU combined with radiation therapy could be used as choices of chemoradiotherapy for esophageal cancer in the future.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Inaba
authors.forename: Takashi
authors.initials: T
authors.lastname: Tsuda
authors.forename: Aya
authors.initials: A
authors.lastname: Miyazaki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nakaya
authors.forename: Yu
authors.initials: Y
authors.lastname: Koitabashi
authors.forename: Kyoko
authors.initials: K
authors.lastname: Ogihara
authors.forename: Takefumi
authors.initials: T
authors.lastname: Hara
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Kato
authors.forename: Yutaro
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Teisuke
authors.initials: T
authors.lastname: Nakagawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kitajima
authors.forename: Toru
authors.initials: T
authors.lastname: Endo
authors.forename: Shiro
authors.initials: S
authors.lastname: Iino
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Hoshikawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011879:Radiotherapy Dosage
chemical_list: D009944:Organoplatinum Compounds; C053989:nedaplatin; D005472:Fluorouracil